Alpha Cognition Inc (TSE:ACOG) has released an update.
Alpha Cognition Inc., a biopharmaceutical company targeting neurodegenerative disorders, has announced its participation in the Emerging Growth Conference on April 3, 2024. The event will feature interactive sessions with the CEO and COO, who will discuss the company’s lead Alzheimer’s treatment, ALPHA-1062. The presentation aims to connect with investors and provide updates, with the opportunity for live Q&A.
For further insights into TSE:ACOG stock, check out TipRanks’ Stock Analysis page.
